Watch the weathercock: changes in re-staging 18F-FDG PET/CT scan predict the probability of relapse in locally advanced non-small cell lung cancer.

INTRODUCTION: Induction treatment is be coming the gold standard for locally advanced non-small cell lung cancers (LA-NSCLC). In contrast to baseline positron emission/computed tomography scan (PET/CT scan), re-staging PET/CT scan has been poorly studied in LA-NSCLC. MATERIALS AND METHODS: We retrospectively explored the efficacy of re-staging PET/CT scan to diagnose response and to predict disease-free survival (DFS) in 55 induction-treated LA-NSCLC further treated with curative surgery or radiation but not with adjuvant therapy. RESULTS: Re-staging N status by PET/CT scan significantly correlated with pathological N status. Radiological or metabolic response in the re-staging PET/CT scan was associated with a significantly better DFS, which decreased from 25.8 to 19.3, to 11.2, and to 9.4 months in cN0, cN1, cN2, and cN3 patients, respectively. CONCLUSION: Re-staging PET/CT scan helps to define response and consolidation treatment in induction-treated LA-NSCLC and predicts DFS. Further extended studies should confirm our results.

Rituximab for induction and maintenance therapy in granulomatosis with polyangiitis (Wegener's). Results of a single-center cohort study on 66 patients.

The aim of this study was to evaluate the efficacy and safety of rituximab (RTX) associated with glucocorticoid treatment based on disease severity, as a remission induction treatment for granulomatosis with polyangiitis (GPA) (Wegener's) and to analyze the results of long-term maintenance therapy with low doses of RTX in a routine time-based protocol. This single-center retrospective study used standardized data collection from all GPA patients receiving RTX between 2002 and 2013. The remission induction regimen consisted of RTX and glucocorticoids, adapted according to disease severity. Once remission was achieved, patients received RTX maintenance treatment (500 mg every 6 months) for 18 months. Sixty-six GPA patients received RTX for remission induction. After six months, a response had been achieved in 78.8% of these patients, with a moderate oral prednisone regimen (mean dose at baseline, 32.8 ± 23.4 mg/day). Subglottic stenosis increased the risk of treatment failure (OR = 31.2, P = 0.0104). RTX maintenance treatment was continued for 18 months in 92% of the GPA patients, who were followed for 34.2 ± 26.2 months (mean total cumulative RTX dose of 4.6 ± 1.7 g). The relapse rate was 11.2/100 patient-years. The relapses occur a mean of 13.5 ± 14.7 months after the last RTX infusion. Twenty-one severe adverse events were recorded; 13.6% patients had severe infections. We conclude that in this single-center cohort, RTX associated with glucocorticoid treatment adapted for disease severity appeared to induce remission effectively in GPA patients. Maintenance treatment with low doses of RTX in a routine time-based protocol was safe and associated with low rates of relapse on treatment.

Evaluación económica de dos variaciones de un tratamiento lactoinductor en vaquillas de reemplazo en un sistema de doble propósito tropical / Economic evaluation of two variations of a hormonal induction treatment in replacement heifers in a tropical dual purpose system

The aim of this study was to evaluate the productivity and profitability of two commercial sources of progesterone therapy as part of a hormonal induction treatment in a heifer dual purpose herd. A second objective was to determine the productivity and profitability of a recombinant bovine somatotropin (ST) application during induced lactation. Forty four Holstein heifers x Zebu crosses were used. Four treatments and two control groups were evaluated. For economic analysis all components of total cost (TC) of the companies were considered, further there was a simulation which was designed for three natural lactations after the hormonal induction, based on two scenarios in which different body weights were considered as different periods. Artificial induction of lactation yielded a 100% success rate in the four groups of animals with no statistical differences between them (P > 0.05). The best cost-benefit ratio (CBR) was recorded by CIDR treatment without ST. Although the four treatments showed economic viability, those without ST had a better ratio (B / C) than those supplemented with ST. As for the net present value (NPV), the benefits updated showed that the profits were higher when ST was not applied and, mainly, in the CIDR treatment. The internal rate of return (IRR) reveals that most of the treatments have a yield above 20%.

Los objetivos del presente trabajo fueron: 1) evaluar la productividad y rentabilidad de dos fuentes comerciales de progesterona como integrantes de un tratamiento lactoinductor en vaquillas de reemplazo de un hato de doble propósito y 2) determinar la productividad y rentabilidad de la aplicación de somatotropina bovina recombinante (ST) durante la lactación inducida. Se usaron 44 novillonas producto de cruzas Holstein x Cebú. Se evaluaron cuatro tratamientos y se manejaron dos grupos testigo. Para el análisis económico se consideraron todos los componentes del costo total (CT) de las empresas, adicionalmente se realizó una simulación en la que se proyectó para tres lactaciones naturales posteriores a la lactoinducción, basadas en dos escenarios en los que se consideraron diferentes pesos corporales como diferentes periodos. En los cuatro grupos de animales lactoinducidos, el 100% de las vaquillas respondió al tratamiento sin diferencias estadísticas entre ellas (P > 0.05). La mejor relación beneficio-costos (RBC) la registró el tratamiento CIDR sin ST. Si bien los cuatro tratamientos presentaron viabilidad económica, los tratamientos sin ST presentaron mejor relación (beneficio/costo) que aquellos tratamientos que sí fueron complementados con ST. En cuanto al valor actual neto (VAN), los beneficios actualizados de todos los años muestran que las utilidades que generaron los tratamientos fueron superiores cuando no se aplicó ST y, principalmente, en el tratamiento con CIDR. La tasa interna de rentabilidad (TIR) revela que la mayoría de los tratamientos tienen una rentabilidad arriba del 20%.